TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18574656
Drug: CFPN-PI for
Normalized name: camphor
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CFPN-PI for 5 days (9-10 mg/kg/day, three times a day)
Study: 15830233
Drug: Delta(9)-THC 10
Normalized name: .DELTA.1-THC
DrugBank: Dronabinol (DB00470)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Delta(9)-THC 10 mg
Study: 15830233
Drug: Delta(9)-THC 20
Normalized name: .DELTA.1-THC
DrugBank: Dronabinol (DB00470)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Delta(9)-THC 20 mg
Study: 15830233
Drug: Delta(9)-THC (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delta(9)-THC (10 and 20 mg)
Study: 9548151
Drug: FSH treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: FSH treatment (60 patients)
Study: 9548151
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment (30 patients)
Study: 9548151
Drug: FSH treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: FSH treatment
Study: 2963532
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g vitamin E/d
Study: 24401815
Drug: 0.45 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.45 g/d eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA)
Study: 24401815
Drug: 0.9 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9 g/d eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA)
Study: 24401815
Drug: 1.8 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.8 g/d eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA)
Study: 9679843
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate (100 microg twice daily)
Study: 15696076
Drug: Montelukast (5-10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast (5-10 mg nightly depending on age)
Study: 14521805
Drug: Weekly doses
Normalized name: selinexor
DrugBank: Selinexor (DB11942)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly doses of cisplatin
Study: 14521805
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 5‐fluorouracil and cisplatin
Study: 10231100
Drug: Ketoprofen 200
Normalized name: ketoprofen 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoprofen 200 mg once daily for 6 weeks
Study: 8542158
Drug: Inhaled glucocorticoid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled glucocorticoid (budesonide 800 micrograms twice daily for 3 weeks)
Study: 1468295
Drug: In vitro
Normalized name: glucuronidase in vitro test
Approvals — FDA: no, EMA: no, PMDA: no
Description: In vitro skills test for insulin preparation
Study: 6398781
Drug: Urokinase: 800,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urokinase: 800,000 CTA units/day for three days followed by oral anticoagulants
Study: 6398781
Drug: Heparin: mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin: mean daily dose 30,000 units for seven days followed by oral anticoagulants
Study: 6398781
Drug: Urokinase: 3,300,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urokinase: 3,300,000 CTA units in 12 hours followed by oral anticoagulants
Study: 17265529
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg dl alpha‐tocopheryl acetate
Study: 17265529
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg beta‐carotene
Study: 12803676
Drug: Statins (HMG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statins (HMG CoA inhibitors)
Study: 2339202
Drug: ONO‐3708 (thromboxane
Approvals — FDA: no, EMA: no, PMDA: no
Description: ONO‐3708 (thromboxane A2 antagonist) administered at a dose of 2 micrograms/kg/min
Study: 28779930
Drug: Whole body
Normalized name: MaxiVision Whole Body Formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole body vibration therapy (WBV) combined with 6 different types of exercises at 30 hz frequency, 2 mm amplitude for 4 weeks
Study: 21722098
Drug: High-volume (26
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-volume (26 ml) ropivacaine 1% with epinephrine
Study: 16385193
Drug: Real-life practice
Normalized name: REAL FOODS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Real-life practice studies (e.g., Triumph project, Quadraet study, ALF-ONE study)
Study: 15244498
Drug: Aciclovir 800
Normalized name: Aciclovir 800 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aciclovir 800 mg + MMF 1 g
Study: 15244498
Drug: Valaciclovir 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valaciclovir 2 g + MMF 1 g
Study: 15244498
Drug: Valaciclovir 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valaciclovir 2 g alone
Study: 15244498
Drug: Aciclovir 800
Normalized name: Aciclovir 800 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aciclovir 800 mg alone
Study: 15244498
Drug: MMF 1
Normalized name: MMF
DrugBank: Monomethyl fumarate (DB14219)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MMF 1 g alone
Study: 9251949
Drug: Ampicillin/sulbactam (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ampicillin/sulbactam (1 g ampicillin plus 0.5 g sulbactam)
Study: 9251949
Drug: Cefotetan (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefotetan (1 g cefotetan)
Study: 8489308
Drug: Operative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Operative treatment in randomized trial
Study: 8489308
Drug: Non-operative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-operative treatment in randomized trial
Study: 27296661
Drug: Innovative combination
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Innovative combination of formal and peer education followed by FibroScan
Study: 24914779
Drug: Pregabalin 75
Normalized name: pregabalin 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin 75 mg twice daily for 5 days
Study: 18390085
Drug: Dinoprostone vaginal
Normalized name: dinoprostone Vaginal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dinoprostone vaginal insert (10 mg) administered for 12 hours without oxytocin (group I)
Study: 18390085
Drug: Dinoprostone vaginal
Normalized name: dinoprostone Vaginal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dinoprostone vaginal insert (10 mg) with oxytocin (group II)
Study: 15012730
Drug: 1‐deamino‐8‐D‐arginine vasopressin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1‐deamino‐8‐D‐arginine vasopressin (dDAVP) administration
Study: 11023260
Drug: Mandibular implant‐supported
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mandibular implant‐supported overdentures
Study: 8993091
Drug: Addition of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Addition of sertraline to ongoing treatment
Study: 8993091
Drug: Clomipramine dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clomipramine dose increase
Study: 30834850
Drug: Table (nutrition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Table (nutrition table with information on energy and main nutrients per 100 g)
Study: 30096878
Drug: 600 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 g/day blackberries (BB, 1500 mg/day flavonoids)
Study: 30096878
Drug: Calorie and
Normalized name: TwoCal HN Calorie and Protein Dense Nutrition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calorie and carbohydrate matched amount of gelatin (GEL, flavonoid-free control)
Study: 21887804
Drug: Fufang Danshen
Normalized name: DANSHEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fufang Danshen capsule 1000 mg twice-daily
Study: 19020291
Drug: Caffeine (9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (9 mg/kg)
Study: 19020291
Drug: Quercetin (2,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quercetin (2,000 mg)
Study: 14756855
Drug: Rofecoxib 25
Normalized name: rofecoxib 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rofecoxib 25 mg or 50 mg daily for 10 days, starting 5 days before menstrual flow.
Study: 9990415
Drug: Tretinoin 0.1%
Normalized name: TRETINOIN 0.1% CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tretinoin 0.1% cream
Study: 9990419
Drug: Tretinoin 0.01%
Normalized name: TRETINOIN 0.01% GEL,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tretinoin 0.01% gel
Study: 9990419
Drug: Tretinoin 0.1%
Normalized name: TRETINOIN 0.1% CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tretinoin 0.1% gel microsphere
Study: 8071051
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg I/mL iopromide
Study: 8071051
Drug: 160 mg
Normalized name: nadolol 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 160 mg I/mL ioversol
Study: 8071051
Drug: 128 mg
Normalized name: citric acid 128 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 128 mg I/mL iopamidol
Study: 22999066
Drug: Red wine
Normalized name: Red wine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Red wine (30 g alcohol/d)
Study: 16291444
Drug: Using the
Normalized name: THE-630
DrugBank: THE-630 (DB16750)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Using the correction factor with 500 mg/dL of p‐Hgb
Study: 12077012
Drug: Post-exercise (31)P‐MRS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-exercise (31)P‐MRS indices of muscle oxidative metabolism in DM and PM patients
Study: 10780258
Drug: Dexamethasone (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (2 mg)
Study: 10780258
Drug: Cocaine (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocaine (12 mg and 50 mg)
Study: 10780258
Drug: Dexamethasone (0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (0 mg)
Study: 2240382
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (1.8 g eicosapentaenoic acid and 1.2 g docosahexaenoic acid)
Study: 2240382
Drug: Corn oil
Normalized name: Corn Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corn oil (3 g linoleic acid)
Study: 337220
Drug: Hypnotic analgesia
Normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hypnotic analgesia procedure
Study: 23135605
Drug: Salvinorin A
Normalized name: Salvinorin A
DrugBank: Salvinorin A (DB12327)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salvinorin A (0.375-21 μg/kg)
Study: 11743506
Drug: Dornase alfa
Normalized name: Dornase Alfa
DrugBank: Dornase alfa (DB00003)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dornase alfa 2.5 mg once daily
Study: 9565416
Drug: L-thyroxine (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-thyroxine (8 microg/kg birth weight per day)
Study: 8168332
Drug: Intravenous ouabain
Normalized name: ouabain
DrugBank: Ouabain (DB01092)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ouabain
Study: 2908528
Drug: KC8702 (new
Approvals — FDA: no, EMA: no, PMDA: no
Description: KC8702 (new method vaccine)
Study: 2908528
Drug: 21A (conventional
Approvals — FDA: no, EMA: no, PMDA: no
Description: 21A (conventional vaccine)
Study: 29231610
Drug: Fire needling
Normalized name: Fire Out
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fire needling therapy applied after ovulation and at the end of the premenstrual stage.
Study: 29231610
Drug: Regular sequential
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular sequential therapy of acupuncture (control group).
Study: 25262192
Drug: Oral gabapentin
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral gabapentin and intradermal injection of lidocaine
Study: 23008027
Drug: Acridine orange
Normalized name: Orange
DrugBank: Orange (DB10549)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acridine orange therapy
Study: 17138198
Drug: Fentanyl iontophoretic
Normalized name: fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl iontophoretic transdermal system (40 mug fentanyl, 10-minute infusion/lockout, up to 6 doses/h)
Study: 17138198
Drug: Morphine intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine intravenous patient-controlled analgesia (1-mg morphine bolus, 5-minute lockout, up to 10 mg/h)
Study: 17138198
Drug: Fentanyl iontophoretic
Normalized name: fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl iontophoretic transdermal system
Study: 20186064
Drug: Morphine intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine intravenous patient-controlled analgesia
Study: 10703677
Drug: Intravenous iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous iron dextran (ivID) protocol, 100 mg loading doses for 2 weeks followed by 25 to 150 mg weekly for 6 months, targeting TSAT between 30 and 50%.
Study: 10703677
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group receiving ivID doses of 25 to 150 mg/week for 6 months, targeting TSAT of 20 to 30%.
Study: 3890032
Drug: Combined chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined chemotherapy using vincristine, dactinomycin, adriamycin, cyclophosphamide until maximum tumor reduction, followed by radiotherapy or surgery on the residual mass only
Study: 9140153
Drug: Omeprazole (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole (80 mg as bolus, followed by 8 mg/h for 72 hours, plus 20 mg orally from day 3 until follow-up on day 21)
Study: 8430920
Drug: Cetirizine 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetirizine 40 mg
Study: 21891871
Drug: Discontinued galantamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinued galantamine treatment
Study: 17932613
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment (trans-sacral magnetic stimulation)
Study: 16626573
Drug: Intracoronary injection
Normalized name: HELIUM 992 mL in 1 L INTRACORONARY GAS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracoronary injection of autologous mesenchymal stem cells (n = 12)
Study: 8247887
Drug: Experimental approach
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental approach to preparation for surgery; details on dosage and duration not available.
Study: 30129666
Drug: Hydrocortisone 200
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Hydrocortisone 200 mg
Study: 18374840
Drug: Insulin lispro
Normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin lispro (thrice daily)
Study: 14571829
Drug: OCM-O group
Normalized name: Padimate O
DrugBank: Padimate O (DB11570)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: OCM-O group (omeprazole 20 mg once daily)
Study: 14571829
Drug: OCM group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: OCM group (without acid suppressing agents)
Study: 10774106
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of 1 g of Dipyrone
Study: 2866338
Drug: Stilboestrol 5
Normalized name: Stilboestrol
DrugBank: Diethylstilbestrol (DB00255)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Stilboestrol 5 mg daily
Study: 24534170
Drug: gelled pectin
Normalized name: Pectin
DrugBank: Pectin (DB11158)
Approvals — FDA: no, EMA: no, PMDA: no
Description: gelled pectin (10 g)
Study: 24534170
Drug: viscous pectin
Normalized name: Pectin
DrugBank: Pectin (DB11158)
Approvals — FDA: no, EMA: no, PMDA: no
Description: viscous pectin (10 g)
Study: 24534170
Drug: capsules
Normalized name: VG capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: capsules
Study: 22417085
Drug: Reduced individualized
Normalized name: Iron, reduced
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reduced individualized GH dose (RID, n=28)
Study: 22417085
Drug: Unchanged individualized
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unchanged individualized GH dose (UID, n=37)
Study: 22417085
Drug: Standard GH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard GH dose (FIX, n=33)
Study: 9266623
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (oral iron + r‐HuEPO)
Study: 8278067
Drug: Meclofenamic acid
Normalized name: Meclofenamic Acid
DrugBank: Meclofenamic acid (DB00939)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Meclofenamic acid 100 mg
Study: 8278067
Drug: Ketoprofene 50
Normalized name: ketoprofen 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoprofene 50 mg
Study: 15747895
Drug: Occupational therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Occupational therapy intervention (EG-IA) - tooth brushing taught and monitored by an occupational therapist
Study: 15747895
Drug: Placebo activity
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo activity (CG-IA) - weekly manicure by the same person
Study: 15747895
Drug: Occupational therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Occupational therapy intervention (EG)
Study: 2079571
Drug: Interferon alfa-2b
Normalized name: Interferon Alfa-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon alfa-2b 3 million units thrice weekly for 14-16 weeks
Study: 37874
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of beta-blockers and diuretics
Study: 31082269
Drug: NAB-paclitaxel 150
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: NAB-paclitaxel 150 mg/m2 (after study amendment, 125 mg/m2)
Study: 31082269
Drug: sb-paclitaxel 80
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: sb-paclitaxel 80 mg/m2
Study: 31082269
Drug: NAB-paclitaxel 125
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: NAB-paclitaxel 125 mg/m2
Study: 31082269
Drug: NAB-paclitaxel 150
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: NAB-paclitaxel 150 mg/m2
Study: 26109117
Drug: Control cream
Normalized name: BENZOYL PEROXIDE 3 mg in 60 mL TOPICAL LIQUID [Acnecare Dermacontrol Cream]
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control cream (Cetomacrogol)
Study: 21550957
Drug: SimpleSTEP (insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: SimpleSTEP (insulin aspart added to the largest meal, titration based on premeal glucose values)
Study: 21550957
Drug: ExtraSTEP (insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: ExtraSTEP (insulin aspart added to the meal with the largest prandial glucose increment, titration based on postmeal glucose values)
Study: 17928808
Drug: Weekly iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly iron supplementation (120 mg elemental iron)
Study: 17928808
Drug: Weekly vitamin
Normalized name: Ezy Dose Weekly Vitamin Planner 2XL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly vitamin A supplementation (25,000 IU)
Study: 17095339
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate (FP) hydrofluoroalkane 88 mug, twice daily
Study: 9507512
Drug: Beta-carotene supplementation
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-carotene supplementation (30 mg dose)
Study: 2680497
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (Milrinone + Digoxin)
Study: 2680497
Drug: Chronic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chronic treatment (3 months)
Study: 1105178
Drug: Live, attenuated
Normalized name: Ebola Zaire vaccine (live, attenuated)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live, attenuated intranasal influenza A vaccine
Study: 27856633
Drug: PARI (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: PARI (2 μg/d) with regular sodium diet
Study: 22744545
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment using the Cotrel-Dubousset method, assessed preoperatively and 12 months postoperatively.
Study: 8542325
Drug: Melatonin (0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin (0.05 mg, 0.5 mg or 5 mg)
Study: 7070696
Drug: Metoprolol (270
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (270 mg/die per os)
Study: 7070696
Drug: Labetalol (270
Approvals — FDA: no, EMA: no, PMDA: no
Description: Labetalol (270 mg/die per os)
Study: 31451207
Drug: Budesonide-formoterol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide-formoterol (200 μg-6 μg Turbuhaler, one inhalation as needed)
Study: 31451207
Drug: Maintenance budesonide
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Maintenance budesonide (200 μg Turbuhaler, one inhalation twice daily) plus terbutaline (250 μg Turbuhaler, two inhalations as needed)
Study: 28114551
Drug: Tapering off
Normalized name: Off! Explore
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tapering off asthma medications over 4 study visits
Study: 26460886
Drug: Higher-dose edoxaban
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher-dose edoxaban (HDE, 60 mg/30 mg)
Study: 26460886
Drug: Lower-dose edoxaban
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower-dose edoxaban (LDE, 30 mg/15 mg)
Study: 25632577
Drug: Mild moxibustion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mild moxibustion of Neixiyan (EX-HE4) and Waixiyan (ST 35) for 30 min, once daily for 14 days, followed by moxibustion of Yaoyangguan (GV 3) and Mingmen (GV 4) once daily for next 7 days.
Study: 25632577
Drug: Mild moxibustion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mild moxibustion of Neixiyan (EX-HE4) and Waixiyan (ST 35) for 30 min, once daily for 14 days (control group).
Study: 19546252
Drug: Cyclophosphamide (CYC)
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide (CYC) 0.75 to 1.3 g as a 2‐hour infusion
Study: 19546252
Drug: Midazolam 1
Normalized name: midazolam 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 1 mg intravenous
Study: 16796640
Drug: Pilocarpine gel
Normalized name: Pilocarpine
DrugBank: Pilocarpine (DB01085)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pilocarpine gel 4%
Study: 1622739
Drug: Intrasplenic arterial
Normalized name: Echinacea, aerial parts
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrasplenic arterial infusion of interleukin-2 (IS-IL-2)
Study: 30962251
Drug: Epidural steroid
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural steroid injection (ESI) in individuals with low non-immune-mediated HR (n=61)